Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Shares Outstanding (Diluted Average): 2021-2024

Historic Shares Outstanding (Diluted Average) for Xeris Biopharma Holdings (XERS) over the last 4 years, with Dec 2024 value amounting to $146.8 million.

  • Xeris Biopharma Holdings' Shares Outstanding (Diluted Average) rose 19.21% to $177.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.6 million, marking a year-over-year increase of 19.21%. This contributed to the annual value of $146.8 million for FY2024, which is 6.61% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Shares Outstanding (Diluted Average) of $146.8 million as of FY2024, which was up 6.61% from $137.7 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' Shares Outstanding (Diluted Average) ranged from a high of $146.8 million in FY2024 and a low of $79.0 million during FY2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $140.0 million, with a median of $137.7 million in 2023.
  • Data for Xeris Biopharma Holdings' Shares Outstanding (Diluted Average) shows a peak YoY surged of 71.62% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Xeris Biopharma Holdings' Shares Outstanding (Diluted Average) stood at $79.0 million in 2021, then surged by 71.62% to $135.6 million in 2022, then rose by 1.51% to $137.7 million in 2023, then climbed by 6.61% to $146.8 million in 2024.